Contrave is not a GLP-1 drug. The two belong to entirely different drug classes, work through different biological pathways, and produce meaningfully different amounts of weight loss. Contrave combines two older medications, naltrexone and bupropion, that act on the brain’s reward and appetite circuits. GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) mimic a gut hormone that regulates hunger, fullness, and how quickly your stomach empties. The confusion is understandable since both are prescribed for weight management, but the similarities mostly end there.
How Contrave Works
Contrave is an oral pill taken daily. It pairs naltrexone, an opioid receptor blocker originally approved for alcohol and opioid dependence, with bupropion, a dopamine reuptake inhibitor approved for depression, seasonal affective disorder, and smoking cessation. Neither drug alone does much for weight loss. Naltrexone on its own has almost no effect on body weight. But together, the two create a synergistic effect on the brain’s appetite-control and reward systems.
Bupropion stimulates certain neurons in the hypothalamus to release a chemical signal that suppresses appetite. The problem is that those same neurons simultaneously release endorphins that shut down the appetite-suppressing signal through a built-in feedback loop. Naltrexone blocks the opioid receptors that endorphins act on, essentially removing the brake that would otherwise limit bupropion’s appetite-suppressing effect. On top of that, naltrexone reduces how pleasurable high-calorie foods taste. In phase III trials, people on the combination reported reduced frequency and strength of food cravings.
1PubMed Central. Reward-Induced Eating: Therapeutic Approaches to Addressing Food CravingsThe net result is that Contrave works primarily by changing how you think about food. It dulls cravings, dampens the rewarding feeling you get from eating certain foods, and reduces overall appetite through central brain circuits. It does not affect your gut, your stomach emptying speed, or the hormones your intestines release after a meal.
How GLP-1 Drugs Work
GLP-1 receptor agonists are injectable medications (with oral forms in development or recently approved for some indications) that mimic a natural hormone called glucagon-like peptide-1. Your body releases this hormone from cells in the gut after you eat, and it does several things at once: it tells your brain you are full, it slows gastric emptying so food stays in your stomach longer, and it helps regulate blood sugar by stimulating insulin release.
2PubMed Central. Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor AgonistsThe pharmaceutical versions of GLP-1 last much longer in the body than the natural hormone, which breaks down within minutes. That sustained presence amplifies every effect. Delayed gastric emptying prolongs the sensation of fullness after eating, which reduces how much food you take in at each meal. In the brain, GLP-1 receptors in the hypothalamus directly stimulate satiety-promoting neurons while indirectly suppressing hunger-promoting ones.
3The American Journal of Medicine. Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy RegulationSo while Contrave works almost exclusively in the brain’s reward centers, GLP-1 drugs attack weight from multiple angles simultaneously: gut motility, central appetite suppression, metabolic regulation, and possibly other pathways researchers are still uncovering. The multi-pronged mechanism helps explain why GLP-1 drugs tend to produce substantially greater weight loss.
The Weight-Loss Gap
This is where the practical differences become stark. In a large phase III trial (COR-II), participants taking Contrave lost about 6.4% of their body weight over 56 weeks compared to 1.2% with placebo. Those who completed the full year of treatment saw about 8.2% weight loss.
4PubMed Central. A Randomized, Phase 3 Trial of Naltrexone SR/Bupropion SR on Weight and Obesity-related Risk Factors (COR-II)GLP-1 drugs operate on a different scale. Semaglutide at the 2.4 mg dose has shown consistent and clinically meaningful weight loss across all its major trials, with long-term efficacy confirmed out to two years.
5PubMed Central. Once-Weekly Semaglutide for Weight Management: A Clinical Review A real-world study found that after one year, people on semaglutide 2.4 mg lost about 14% of their body weight, while those on tirzepatide lost roughly 16.5%.
6PubMed Central. Real-World Weight Loss Observed With Semaglutide and Tirzepatide in Patients with Overweight or Obesity and Without Type 2 Diabetes (SHAPE)To put that in everyday terms: on Contrave, someone weighing 220 pounds might expect to lose roughly 14 pounds over a year. On semaglutide, the same person might lose around 30 pounds. On tirzepatide, closer to 36. These are averages and individual responses vary considerably, but the magnitude of difference is not subtle. GLP-1 drugs produce roughly two to three times more weight loss than Contrave in most head-to-head comparisons and across-trial analyses.
Different Side-Effect Profiles
Because the two drug classes work through different body systems, the side effects you can expect are different too. Contrave’s most common complaints mirror its parent drugs: nausea, headache, constipation, dizziness, insomnia, and dry mouth. The nausea tends to be worst during the first few weeks while you titrate up to the full dose. Because bupropion lowers the seizure threshold, Contrave is contraindicated in people with seizure disorders, eating disorders like bulimia or anorexia, or those undergoing abrupt withdrawal from alcohol or sedatives.
GLP-1 drugs bring a different set of concerns. Gastrointestinal side effects dominate: nausea, vomiting, diarrhea, and constipation are the most frequently reported problems.
7PubMed Central. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus These stem directly from the mechanism of action: slowing gastric emptying and changing gut motility inevitably makes the digestive system complain, especially early on. For most people, the GI symptoms ease over weeks to months as the body adjusts. Rare but more serious concerns with GLP-1 drugs include pancreatitis and, in animal studies, thyroid tumors, though how that translates to human risk remains under investigation.
In short, Contrave’s side effects lean neurological and psychiatric (reflecting its brain-based mechanism), while GLP-1 side effects lean gastrointestinal (reflecting their gut-based mechanism). Neither profile is necessarily milder than the other; which matters more depends on your individual health history.
Who Might Be a Better Fit for Contrave
Given the weight-loss gap, you might wonder why anyone would choose Contrave. There are real scenarios where it makes sense. Contrave acts on the brain’s reward centers, making it a reasonable option for people whose weight gain is driven by emotional eating, carbohydrate cravings, stress-related overeating, or habitual alcohol use. Because bupropion has antidepressant properties, Contrave can be particularly well-suited for patients dealing with mood-related eating patterns. A clinical review on patient-centered medication selection noted that naltrexone/bupropion is worth considering for patients who eat emotionally or who have strong carbohydrate cravings, though it should be avoided in those with eating disorders like bulimia or anorexia.
8Korean Journal of Family Medicine. Obesity Pharmacotherapy: A Practical Approach to Patient-Centered Medication SelectionContrave is also an oral medication, which matters to people who cannot or will not do weekly injections. It is available as a generic (as of recent years, the individual components have been generic for a long time), which makes it considerably cheaper than branded GLP-1 injectables, whose list prices can run over $1,000 a month without insurance. For someone who needs modest weight loss and has insurance barriers or needle aversion, Contrave remains a practical choice. It may also be preferred for patients already taking medications that interact poorly with GLP-1 drugs, or for those with a history of pancreatitis or medullary thyroid cancer, where GLP-1 agonists are contraindicated.
Cardiovascular Considerations
Cardiovascular safety has been a point of tension for Contrave and an area of emerging strength for GLP-1 drugs. Contrave’s path to FDA approval was rocky. The FDA initially rejected it in part because of concerns about cardiovascular risk.
9Disease Models & Mechanisms. Anti-obesity drugs: past, present and future A cardiovascular outcomes trial called LIGHT was subsequently launched but ended up mired in controversy when data were prematurely released. At the interim 50% analysis point, major adverse cardiovascular events had occurred in 90 patients on Contrave versus 102 on placebo, and Contrave patients lost about 3.9 kg compared to 1.2 kg with placebo.
10TCTMD. Controversial LIGHT Trial Now Published but Fails to Illuminate CV Risks of Contrave But because the trial was compromised and never completed as designed, it was unable to definitively rule cardiovascular risk in or out. Contrave’s label still carries a warning that its cardiovascular effects have not been established.
GLP-1 drugs, by contrast, have accumulated strong cardiovascular evidence. Semaglutide has been shown to reduce the risk of major cardiovascular events in people with established cardiovascular disease, leading to expanded indications beyond just weight management or diabetes. This has given GLP-1 drugs a significant edge in patients who have or are at high risk for heart disease.
What Happens When You Stop
Weight regain after discontinuation is a concern with both drug classes, but the data on GLP-1 drugs is particularly well documented. A meta-analysis found that after stopping GLP-1 receptor agonists, people regained an average of about 4 kg, with waist circumference increasing by roughly 3.6 cm. From the original study baseline through the end of follow-up (including the regain period), GLP-1 treatment still left patients with a net weight loss of about 2.3 kg, meaning they didn’t bounce all the way back to where they started, but they did lose a substantial portion of their progress.
11SpringerLink / Journal of General Internal Medicine. Effects of Glucagon-Like Peptide-1 Receptor Agonists After Treatment Withdrawal: A Systematic Review and Meta-AnalysisContrave shows a similar pattern in clinical practice: weight tends to return when the medication is stopped, because the underlying biology that drives overeating reasserts itself. Neither drug class cures obesity. Both are more like corrective lenses for appetite regulation than one-time fixes. This is worth knowing upfront because it affects how you plan treatment duration and what to expect if you discontinue for any reason, whether by choice, insurance changes, or supply shortages.
Combining Contrave and GLP-1 Drugs
Because the two drugs work through entirely separate pathways, some clinicians have started prescribing them together, particularly for patients who plateau on a GLP-1 drug alone. This is off-label, meaning neither drug is specifically approved for use in combination with the other. But a retrospective study found that adding bupropion/naltrexone to an existing GLP-1 regimen was associated with about 4% additional total body weight loss, and this held true whether the patient had been responding well to the GLP-1 drug or had stalled.
12PubMed. Effect of combined GLP-1 analogue and bupropion/naltrexone on weight loss: a retrospective cohort studyThe logic is intuitive: if one drug reduces hunger and slows your stomach while the other dials down food cravings and reward-driven eating, the two could complement each other. Someone on semaglutide who no longer overeats from physical hunger but still struggles with emotional eating or craving-driven snacking might benefit from adding Contrave. The evidence is still early and comes from observational data rather than randomized controlled trials, so the combination is not standard practice. But it underscores the point that these are genuinely different tools acting on different problems.
Administration, Cost, and Access
The practical logistics of taking these drugs differ in ways that affect daily life. Contrave is a twice-daily oral tablet, titrated up over four weeks to its maintenance dose. It requires no refrigeration, no injection supplies, and no healthcare-provider visits for administration. GLP-1 drugs for weight management (semaglutide as Wegovy, tirzepatide as Zepbound) are typically injected once weekly using a prefilled pen. The injection is subcutaneous and most people manage it at home without difficulty, but needle aversion is real and can be a dealbreaker for some patients.
Cost is where the gap becomes especially wide. Contrave’s list price is lower than branded GLP-1 injectables, and generic versions of naltrexone and bupropion individually are very inexpensive, though the specific combination tablet may still carry a higher price. Branded GLP-1 injectables for weight loss remain among the most expensive medications on the market. Insurance coverage varies enormously. Many insurers cover GLP-1 drugs for type 2 diabetes but exclude or restrict coverage for weight management alone, pushing patients toward cheaper alternatives like Contrave. Supply shortages of GLP-1 drugs, which have been widespread since their popularity surged, add another layer of unpredictability that Contrave does not share.
Contrave’s Regulatory History
Contrave’s path to approval tells you something about why it occupies a different tier than GLP-1 drugs in current clinical thinking. The FDA initially rejected the naltrexone/bupropion combination due to cardiovascular safety concerns, requesting a large outcomes trial before granting approval.
9Disease Models & Mechanisms. Anti-obesity drugs: past, present and future It was eventually approved in 2014, but with the caveat that a postmarketing cardiovascular outcomes trial needed to be completed. That trial, LIGHT, was derailed by a premature data leak, leading the FDA to conclude the trial could no longer provide interpretable results. Contrave thus exists in a somewhat unusual regulatory position: approved and on the market, but without the definitive cardiovascular safety data the FDA originally wanted.
GLP-1 drugs, by contrast, arrived on the weight-loss scene with robust cardiovascular outcomes data already in hand from their diabetes indications. Semaglutide’s STEP trials for obesity built on top of a solid evidence base from the SUSTAIN and PIONEER programs for type 2 diabetes. This deeper body of evidence, including a dedicated cardiovascular outcomes trial (SELECT) showing reduced heart attack and stroke risk in people with obesity, has positioned GLP-1 drugs as the dominant class in modern obesity pharmacotherapy.
GLP-1 Drugs in Younger Patients
One area where GLP-1 drugs have expanded that Contrave has not is adolescent obesity. A trial of once-weekly semaglutide in adolescents found a mean BMI reduction of about 16% from baseline over 68 weeks, compared to a slight increase in the placebo group. Roughly three-quarters of the semaglutide group achieved at least 5% weight loss.
13PubMed Central. Once-Weekly Semaglutide in Adolescents with Obesity These results led to FDA approval of semaglutide for adolescents aged 12 and older with obesity, giving clinicians a pharmacological option for a population where behavioral interventions alone often fall short. Contrave, by contrast, is approved only for adults and has not been studied in pediatric obesity in the same way.
The adolescent data also highlight a broader trend: GLP-1 drugs are being studied across more populations and for more conditions (heart failure, kidney disease, liver disease, addiction) than Contrave, which remains positioned primarily as an adult weight-management drug with a secondary niche in craving reduction. The research trajectories of these two drug classes have diverged dramatically in recent years, with GLP-1 agonists attracting the lion’s share of funding, clinical-trial activity, and medical interest.